Recursion Pharmaceuticals, Inc. CEO and President Najat Khan filed a Form 4 on November 18, 2026, disclosing a transaction dated November 16, 2026, in which 85,815 shares of Class A Common Stock were withheld by the issuer to cover tax obligations connected to the net settlement of restricted stock units.
Key Highlights
- Reporting person: Najat Khan, CEO and President, and Director of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
- Transaction date: November 16, 2026
- Transaction code: F (shares withheld for tax withholding and remittance on RSU net settlement)
- Shares withheld: 85,815 shares of Class A Common Stock disposed of at $3.185 per share
- Remaining beneficial ownership: 1,987,075 shares of Class A Common Stock held directly following the transaction
- No derivative securities were reported as acquired or disposed of in this filing
RSU Tax Withholding Reduces Khan's Direct Stake in Recursion Pharmaceuticals
According to the filing, Najat Khan, who serves as CEO, President, and Director of Recursion Pharmaceuticals, Inc., reported the disposition of 85,815 shares of Class A Common Stock on November 16, 2026. The filing identifies the transaction code as "F," and the accompanying footnote states that the shares "have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units." The price recorded for the transaction was $3.185 per share.
Following this disposition, the filing reports that Khan directly holds 1,987,075 shares of Class A Common Stock. The form was signed by Kyle Nelson as attorney-in-fact on November 16, 2026, and filed with the SEC on November 18, 2026. No indirect ownership or derivative securities positions were reported in Table I or Table II of the filing.
The filing was submitted pursuant to Section 16(a) of the Securities Exchange Act of 1934, which requires officers and directors to report changes in their beneficial ownership of company securities. No amendment to a prior filing was indicated.
What Was Disclosed
Recursion Pharmaceuticals CEO and President Najat Khan disclosed that 85,815 shares of Class A Common Stock were withheld by the company at $3.185 per share on November 16, 2026, to satisfy tax obligations on RSU net settlement, leaving Khan with 1,987,075 directly held shares.




Please wait processing your request...